{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lacerations/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"3713be7a-1d15-503e-9cdb-6d3afe60f335","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 6570e612-9118-416c-91c9-df4fbc68835c --><h2>Changes</h2><!-- end field 6570e612-9118-416c-91c9-df4fbc68835c -->","summary":null,"htmlStringContent":"<!-- begin item 15adc209-87bb-437f-9b60-c3c0218b4089 --><!-- begin field f165a26d-d238-4bb5-9d46-7035dc5e8a98 --><p><strong>January 2021</strong> — minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update. </p><!-- end field f165a26d-d238-4bb5-9d46-7035dc5e8a98 --><!-- end item 15adc209-87bb-437f-9b60-c3c0218b4089 -->","topic":{"id":"bc1075da-03fb-510a-aafc-42f8402c77bb","topicId":"c455b3ad-86f5-4c2b-a00d-ceb66ba46f46","topicName":"Lacerations","slug":"lacerations","lastRevised":"Last revised in January 2021","chapters":[{"id":"abcb9c5e-8c70-578e-b2f1-2bfe9e0e6dea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b3295eac-08d7-597e-9bbf-240c812490a5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0f6da996-76f9-5508-aead-4f7d04fc2910","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3713be7a-1d15-503e-9cdb-6d3afe60f335","slug":"changes","fullItemName":"Changes"},{"id":"d164a0e0-2763-5ec6-8aaa-1f68fe1d381c","slug":"update","fullItemName":"Update"}]},{"id":"e6d917bb-ce9e-58a6-8b13-cf3e389a6aef","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"83820372-5bd1-5e60-a139-cd76615ac683","slug":"goals","fullItemName":"Goals"},{"id":"15606cb7-089f-5a7d-af3f-d4b9c9b0d2be","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1a9aa28b-0708-5c58-843c-05a09196b471","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"682e483f-7847-5e82-be10-969f896d9533","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0db2153f-bcb4-5382-9178-92d651a01c4e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3929f359-184e-53d4-8aca-a4081b967c1a","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"313e7f7d-a625-5b48-a31d-e5f00ca31462","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0ad26899-0f07-5523-8ea6-17d520df4cc8","slug":"definition","fullItemName":"Definition"},{"id":"e917af1e-ca7f-5ddd-9cb9-1132ce21b4a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe57a056-8e82-56fa-bb79-87f037fb4303","slug":"complications","fullItemName":"Complications"}]},{"id":"e01eac70-aab4-50c3-a90e-7b07194bf1c8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c1be68cd-346e-504f-b22f-e8352fc5c3f6","slug":"assessment","fullItemName":"Assessment"}]},{"id":"35a250d2-9a3b-5287-8afa-d73dfc12c39b","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c6adc10-cc7f-5820-b2da-874e89c9b72b","slug":"laceration-low-infection-risk","fullItemName":"Scenario: Laceration - low infection risk"},{"id":"496fa19f-131c-5dd3-8be3-ae041478b608","slug":"laceration-high-infection-risk","fullItemName":"Scenario: Laceration - high infection risk"},{"id":"9204ec1a-d022-5955-9f74-6b4eb51bf9a9","slug":"laceration-infected","fullItemName":"Scenario: Laceration - infected"}]},{"id":"ae2f2d25-ab30-53a1-8eff-d3fb8c5994f9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ffdfa8df-e6e7-56b4-99c6-dfe62dda65a2","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f4667375-a12d-57c4-a82a-192c500b41bb","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"8d7c7214-71fc-5171-9875-f310b20c40cb","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"23d49e6f-7a37-5188-8b3f-6b6fdb671019","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"f3f77580-8498-590e-a7c3-0afbee563567","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8f912e41-1ff8-5fce-b9b4-6b3524e8f79b","slug":"tetanus-booster","fullItemName":"Tetanus booster"}]},{"id":"b1fc897d-bfab-5305-bcf1-70e0f4598e5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"18a38028-bff4-54de-948c-9715f3649589","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0132c748-edac-513b-a351-59a838b07e61","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b4b28cd4-4652-528e-aa28-23f341c6a31e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b86d931b-dadb-55a7-92c8-6cdb81ce5d7f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f6695afc-2f21-5bf7-907b-68a0fb3a77c4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d4ab79d3-d601-5b9b-b2b5-d3256e138671","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc9ca4ec-c56f-5acc-830c-ccf5c31d5f67","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0f6da996-76f9-5508-aead-4f7d04fc2910","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ca9fdb5e-1c4d-5927-8702-701a8c887684","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 02bbb0fc-9d85-46a1-869d-d2ee5e495bea --><h3>Previous changes</h3><!-- end field 02bbb0fc-9d85-46a1-869d-d2ee5e495bea -->","summary":null,"htmlStringContent":"<!-- begin item 1ecc6743-b51d-4deb-a752-1df284f3ebe2 --><!-- begin field 8b85bef2-3520-474c-92ac-88820773d248 --><p><strong>October 2018 </strong>— minor update. Adverse effects updated within prescribing information - metronidazole. </p><p><strong>June 2017 </strong>— reviewed. A literature search was conducted in May 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>July 2015 </strong>— minor update. Links to the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> and <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a> have been added to the section on Prescribing information.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic. </p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.   </p><p><strong>August 2012 </strong>— reviewed. A literature search was conducted in August 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>July 2011 </strong>— minor update. More exact paracetamol dosing for children has been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA). Prescriptions have been updated to reflect the revised dosing. Issued in July 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>October 2010 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>August 2009 </strong>— minor update. Advice from the National Institute for Health and Care Excellence (NICE) guideline on when to suspect child maltreatment has been added to this topic. Issued in August 2009.</p><p><strong>July to October 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. More detailed information has been included on how to assess and manage a laceration at high risk of infection.</p><p><strong>October 2006 </strong>— minor update. Analgesia prescriptions have been updated because new doses of ibuprofen for children are recommend in the British National Formulary (BNF). Issued in October 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>July 2005 </strong>— minor correction to reference list. Issued in July 2005.</p><p><strong>September 2004 </strong>— updated to include the new combined tetanus vaccines Pediacel®, Repevax®, and Revaxis®. Issued in September 2004.</p><p><strong>March 2004 </strong>— reviewed. Validated in May 2004 and issued in July 2004.</p><p><strong>May 2001</strong> — reviewed. Validated in July 2001 and issued in October 2001.</p><p><strong>August 1998 </strong>— written.</p><!-- end field 8b85bef2-3520-474c-92ac-88820773d248 --><!-- end item 1ecc6743-b51d-4deb-a752-1df284f3ebe2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}